Cancer

In immuno-oncology and companion diagnostics, detection antibodies are critical reagents for precise biomarker quantification. From PD-L1 IHC pathological assessment to CAR-T efficacy monitoring, high-affinity, low-cross-reactivity antibodies directly determine the accuracy of HER2, EGFR, and MSI-H target expression. In research, these antibodies underpin tumor microenvironment profiling, neoantigen screening, and resistance mechanism studies. As bispecific antibodies, ADCs, and personalized cancer vaccines advance, demands for batch-to-batch consistency, signal-to-noise ratio, and comprehensive validation data intensify. Selecting rigorously validated detection antibody systems is essential to ensure experimental reproducibility and data interoperability.